GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
-0.03%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$207M
AUM Growth
+$207M
(-25%)
Cap. Flow
-$27.9M
Cap. Flow
% of AUM
-13.5%
Top 10 Holdings %
Top 10 Hldgs %
43.1%
Holding
75
New
17
Increased
13
Reduced
15
Closed
14
Top Buys
| 1 |
Krystal Biotech
KRYS
|
$6.96M |
| 2 |
Immunovant
IMVT
|
$4.99M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
$4.44M |
| 4 |
Taysha Gene Therapies
TSHA
|
$4.19M |
| 5 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$4.13M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$16.4M |
| 2 |
Akero Therapeutics
AKRO
|
$12.4M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$8.67M |
| 4 |
Vaxcyte
PCVX
|
$7.14M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
$6.13M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $18.8M | 6.19% | 330,000 | – | – |
|
|
2
Krystal Biotech
KRYS
$4.27B
| $9.28M | 3.05% | 80,000 +60,000 | +300% | +$6.96M |
|
3
Madrigal Pharmaceuticals
MDGL
$9.76B
| $8.4M | 2.76% | 57,500 +2,500 | +5% | +$365K |
|
4
TG Therapeutics
TGTX
$4.65B
| $8.36M | 2.75% | 1,000,000 +175,000 | +21% | +$1.46M |
|
5
Ascendis Pharma
ASND
$11.8B
| $7.96M | 2.62% | 85,000 -15,000 | -15% | -$1.4M |
|
6
Axsome Therapeutics
AXSM
$6.05B
| $7.69M | 2.53% | 110,000 | – | – |
|
|
ALPN
7
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $7.6M | 2.5% | 664,132 +316,700 | +91% | +$3.63M |
|
|
8
Vaxcyte
PCVX
$4B
| $7.14M | 2.35% | 140,000 -140,000 | -50% | -$7.14M |
|
|
9
Tarsus Pharmaceuticals
TARS
$2.47B
| $7.11M | 2.34% | 400,000 +250,000 | +167% | +$4.44M |
|
10
Protagonist Therapeutics
PTGX
$3.67B
| $6.67M | 2.19% | 400,000 +175,000 | +78% | +$2.92M |
|
11
Cogent Biosciences
COGT
$1.69B
| $6.34M | 2.08% | 650,000 +75,000 | +13% | +$731K |
|
|
AMAM
12
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $6.04M | 1.99% | 525,000 +286,775 | +120% | +$3.3M |
|
|
13
Akero Therapeutics
AKRO
$3.74B
| $5.82M | 1.91% | 115,000 -245,000 | -68% | -$12.4M |
|
|
14
Immunovant
IMVT
$2.56B
| $4.99M | 1.64% | +130,000 | New | +$4.99M |
|
15
Sarepta Therapeutics
SRPT
$1.78B
| $4.85M | 1.59% | 40,000 -45,000 | -53% | -$5.45M |
|
16
PMV Pharmaceuticals
PMVP
$74.2M
| $4.33M | 1.43% | 705,881 +424,900 | +151% | +$2.61M |
|
17
Viridian Therapeutics
VRDN
$1.5B
| $4.22M | 1.39% | 275,000 +35,000 | +15% | +$537K |
|
|
18
Taysha Gene Therapies
TSHA
$797M
| $4.19M | 1.38% | +1,325,000 | New | +$4.19M |
|
|
DCPH
19
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $4.13M | 1.36% | +325,000 | New | +$4.13M |
|
20
Phathom Pharmaceuticals
PHAT
$864M
| $4.1M | 1.35% | 395,000 +240,750 | +156% | +$2.5M |
|
|
RVNC
21
DELISTED
Revance Therapeutics, Inc.
RVNC
| $4.01M | 1.32% | 350,000 -175,000 | -33% | -$2.01M |
|
|
22
Amylyx Pharmaceuticals
AMLX
$836M
| $3.94M | 1.29% | 215,000 -335,000 | -61% | -$6.13M |
|
23
Xenon Pharmaceuticals
XENE
$2.98B
| $3.38M | 1.11% | 98,951 -86,049 | -47% | -$2.94M |
|
24
Crinetics Pharmaceuticals
CRNX
$2.92B
| $3.02M | 0.99% | +101,443 | New | +$3.02M |
|
25
Syndax Pharmaceuticals
SNDX
$1.41B
| $2.9M | 0.96% | 200,000 -150,000 | -43% | -$2.18M |
|